<DOC>
	<DOCNO>NCT00003946</DOCNO>
	<brief_summary>RATIONALE : Hormone therapy may effective treatment endometrial cancer . PURPOSE : Phase II trial study effectiveness danazol treat patient advanced recurrent endometrial cancer .</brief_summary>
	<brief_title>Danazol Treating Patients With Advanced Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity danazol patient advance recurrent endometrial cancer . II . Determine nature toxicity danazol patient . OUTLINE : Patients receive oral danazol 4 time per day least 4 week . Patients partial response , complete response , stable disease continue treatment absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 23-56 patient accrue study within 26 month .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Danazol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced recurrent endometrial cancer amenable curative surgery radiotherapy Measurable disease Tumor least 1.0 cm 1.0 cm per xray physical exam OR Tumor least 2.0 cm 2.0 cm per CT scan , MRI , ultrasound PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3000/mm3 Platelet count least 100,000/mm3 No history porphyria Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 2 mg/dL Other : No concurrent prior malignancy within past 5 year ( except nonmelanoma skin cancer ) patient receive chemotherapy Not pregnant nursing Fertile patient must use effective contraception Must tissue available estrogen receptor/ progesterone receptor analysis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : At least 3 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>